Biogen Q2 2023 Earnings Preview
Biogen (NASDAQ:BIIB) is scheduled to announce Q2 earnings results on Tuesday, July 25th, before market open.
The consensus EPS Estimate is $3.76 (-28.4% Y/Y) and the consensus Revenue Estimate is $2.36B (-8.9% Y/Y).
During the company's Q2 earnings conference call, market participants expect information on the recently licenced Alzheimer's treatment, Leqembi, as well as progress on the company's cost-cutting initiatives and management's thoughts on the depression therapy zuranolone.

Over the last 2 years, BIIB has beaten EPS estimates 88% of the time and has beaten revenue estimates 100% of the time.
Over the last 3 months, EPS estimates have seen 8 upward revisions and 14 downward. Revenue estimates have seen 3 upward revisions and 18 downward.
The stock gets a consensus Buy recommendation from Wall Street analysts as opposed to a Hold rating from Seeking Alpha's Quant Rating system, which has flagged concerns about growth and valuation.

More on Biogen

Biogen And Alzheimer's Disease: Too Early To Celebrate
Biogen/Eisai's Leqembi set to become Medicare's single highest drug spend